Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to Knopp.
Gazi
Irene F
IF
Mikhailidis
Dimitri P
DP
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D003327:Coronary Disease / Q000150:complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D011758:Pyrroles / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin